Zai Lab (09688) saw its shares rise more than 5% again, with an increase of 5.1% to HK$15.26 by the time of writing. The trading volume reached HK$81.9741 million. On February 9, Zai Lab's injectable ZL-1310 was proposed for inclusion in the breakthrough therapy designation. It is intended for patients with extensive-stage small cell lung cancer (ES-SCLC) who have experienced disease progression during or after first-line platinum-containing therapy. ZL-1310 has demonstrated highly promising efficacy data in early-stage clinical studies, showing high response rates particularly in second-line and later treatments, as well as in patients with brain metastases. This positions it as a potential breakthrough therapy in the SCLC treatment landscape. Haitong International previously released a research report stating that the company generates stable revenue by introducing and commercializing overseas products while leveraging its cross-border platform to advance the global development of innovative pipelines. Among its core pipelines, the DLL3-targeting ADC drug Zocilurtatug is planned to initiate three registration clinical trials by the end of 2026, covering small cell lung cancer and neuroendocrine carcinoma. Additionally, the company possesses several early-stage global assets with differentiated potential, such as ZL-1503 and ZL-6201, which collectively support its long-term value creation.